BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $9.70 (167.96% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016FBR & CoReiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Jefferies GroupUpgradeHold -> Buy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$16.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$15.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016JMP SecuritiesLower Price Target$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Bank of America Corp.DowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.21)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.17)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.20)($0.23)
Q2 20165($0.25)($0.17)($0.22)
Q3 20165($0.26)($0.16)($0.22)
Q4 20165($0.26)$0.12($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline
07/29/16 02:48 PMHot Biotech Stocks Recap: BioCryst Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar
07/29/16 05:59 AM8 Stocks Under $10 to Trade for Huge Profits -
07/28/16 11:33 AMAnalysts Observable Stocks: Exelixis, Inc. (NASDAQ:EXEL) , BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Street Updates
07/28/16 11:33 AMBioCryst Pharmaceuticals Inc. (BCRX) Jumps 13.67% on July 27 - Equities.com
07/28/16 07:25 AMBioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7% -
07/26/16 10:36 AMCan BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Surprise Analysts this Quarter? - Investor Newswire
07/25/16 08:53 PMCan Shares Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hit $16? - Investor Newswire
07/22/16 02:44 PMEarnings Focus and Crowd Sourced Sentiment Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TGP
07/21/16 06:15 AMBioCryst to Announce Second Quarter 2016 Financial Results August 4 - [GlobeNewswire] - RESEARCH TRIANGLE PARK, N.C., July 21, 2016-- BioCryst Pharmaceuticals, Inc. today announced that its second quarter 2016 financial results will be released on Thursday, August 4, 2016. BioCryst will host ...
07/20/16 10:50 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/19/16 02:47 PMBiocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Sellers Increased By 1.14% Their Shorts - Consumer Eagle
07/19/16 02:47 PMIs $16 Price Target Attainable For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)? - Investor Newswire
07/17/16 02:41 PMWere Analysts Bullish BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Week? - Consumer Eagle
07/17/16 02:41 PMNext Weeks Broker Price Targets For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Fiscal Standard
07/16/16 02:46 PMBiocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Shorted Shares Decreased By 11.95% - Press Telegraph
07/16/16 08:43 AMAlliqua Biomedical Inc (NASDAQ:ALQA) went up 4.24%: BioCryst Pharmaceuticals (NASDAQ:BCRX), AK Steel ... - KC Register
07/16/16 08:43 AMShares Experiencing a Downtrend: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TGP
07/16/16 08:43 AMBioCryst Pharmaceuticals Inc. (BCRX) Drops 5.21% on July 13 - Equities.com
07/14/16 11:40 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 11:40 AMBioCryst Pharmaceuticals Inc Stock Momentum Hits Extreme Weakness - CML News
07/14/16 11:40 AMInsiders Increasing Positions in: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Press Telegraph
07/12/16 02:50 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Fundamental Star Rating Report - CML News
07/12/16 04:43 AMTrading Performance and Target Watch for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Press Telegraph
07/12/16 04:43 AMStrong Sell Calls For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) At 0 - Investor Newswire
07/11/16 02:46 PMWhy Need to Watch: Identiv, Inc. (NASDAQ:INVE), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ICU Medical, Inc ... - KC Register
07/11/16 02:46 PMStock on the Rise for the Quarter: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Engelwood Daily
07/09/16 02:41 PMWall Street Ratings and Target Price Views on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Telanagana Press
07/09/16 02:41 PMAre Analysts Bullish BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Last Week? - Press Telegraph
07/07/16 01:45 PMETF’s with exposure to BioCryst Pharmaceuticals, Inc. : July 7, 2016 -
07/07/16 10:41 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/07/16 10:41 AMOption Market: BioCryst Pharmaceuticals Inc. Risk Hits An Elevated Level - CML News
07/06/16 07:36 AMStock Rating Watch and Earnings Insight for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Press Telegraph
07/05/16 02:48 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Reach Highs Of $16 - Investor Newswire
07/05/16 02:48 PMShare Volatility in Focus: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Engelwood Daily
07/05/16 07:11 AMBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial -
07/05/16 06:41 AMBioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases - [at noodls] - RESEARCH TRIANGLE PARK, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided ...
07/05/16 06:32 AM7:32 am BioCryst Pharma announces that the National Institute of Allergy and Infectious Diseases has provided additional funding of $5.5 mln for efficacy studies of BCX4430 as a treatment for hemorrhagic fever viruses -
07/04/16 02:43 PMShare Performance Recap for: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Press Telegraph
06/30/16 08:16 PMWhat's Next for BioCryst Pharmaceuticals, Inc. After Today's Huge Decline? - Engelwood Daily
06/30/16 10:38 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Company Rating and Target Watch - Telanagana Press
06/29/16 11:00 AMBioCryst Pharmaceuticals Inc. (BCRX) Jumps 5.64% on June 28 - Equities.com
06/28/16 08:07 PMShort Interest Falls 12% For BCRX
06/28/16 07:12 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 07:12 AMStrong Sell Calls Recommendations For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) At 0 - Investor Newswire
06/27/16 02:25 PMNew Broker Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - FTSE News
06/25/16 06:13 AMWere Analysts Bearish BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Week? - Press Telegraph
06/24/16 07:56 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Updated Price Targets - FTSE News
05/31/16 11:31 AMMost Popular Healthcare Stocks Under $5 -
05/31/16 08:15 AMEarly Morning Technical Highlights on Biotech Stocks -
05/26/16 06:19 PMETF’s with exposure to BioCryst Pharmaceuticals, Inc. : May 26, 2016 -

Social

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company's Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BCRX
  • CUSIP: 09058V10
Key Metrics:
  • Previous Close: $3.46
  • 50 Day Moving Average: $2.98
  • 200 Day Moving Average: $3.42
  • P/E Ratio: N/A
  • P/E Growth: -0.16
  • Market Cap: $266.77M
  • Beta: 3.05
  • Current Year EPS Consensus Estimate: $-1.03 EPS
  • Next Year EPS Consensus Estimate: $-0.9 EPS
Additional Links:
BioCryst Pharmaceuticals (NASDAQ:BCRX) Chart for Saturday, July, 30, 2016